SCHEMBL5763574

SCHEMBL5763574

O=c1cc(C(F)(F)F)c2cc(Cc3ccc(S(=O)(=O)Nc4ccc(Cl)cc4)cc3)ccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.50
FFAR4 Q5NUL3 2/20 0.48
FFAR1 O14842 1/20 0.48
AR P10275 2/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CES1 P23141 1/20 0.44
PKM P14618 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
ERAP1 Q9NZ08 1/20 0.43
HSPD1 P10809 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN5 P54829 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759426 0.91 PKM (0.53) FFAR4FFAR1ARCA1CA2
SCHEMBL5860039 0.90 PKM (0.43) HTTFFAR4ARPKMMEN1
SCHEMBL5760427 0.90 KDM4E (0.48) FFAR4FFAR1ARPKMMEN1
SCHEMBL5760245 0.90 KMT2A (0.55) HTTFFAR4ARPKMMEN1
SCHEMBL5761750 0.90 KDM4E (0.46) FFAR4ARPKMMEN1KMT2A
SCHEMBL5761019 0.89 AR (0.48) FFAR4ARPKMMEN1KMT2A
SCHEMBL5860303 0.88 PKM (0.41) HTTFFAR4ARPKMMEN1
SCHEMBL5762376 0.88 PKM (0.41) HTTFFAR4ARPKMMEN1
SCHEMBL5760067 0.87 PKM (0.46) HTTFFAR4ARCA1CA2
SCHEMBL5860372 0.87 PKM (0.41) HTTFFAR4ARCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US claimed
EP-1633732-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2006-03-15 EP claimed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US claimed
WO-2004101544-A1 BENZYL SULFONAMIDE DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-11-25 WO claimed
US-7098340-B2 Quinoline/chromene derivatives as androgen antagonist WARNER LAMBERT COMPANY LLC (US) 2006-08-29 US disclosed
US-20050137228-A1 Benzyl sulfonamide derivatives DU DANIEL Y (US) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137228-A1 Benzyl sulfonamide derivatives AR, SHBG, BRDT HTT 2718/4885FFAR4 550/4885FFAR1 624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.